Asia-Pacific Schizophrenia Drugs Market Research Report – Segmented By Therapeutic Class, Treatment & Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC) – Industry Size, Share, Trends & Growth Forecast (2022 to 2027)
The size of the Asia Pacific Schizophrenia Drugs Market was worth USD 1.43 billion in 2022. This value is estimated to be growing at a CAGR of 2.78%, to reach USD 1.64 billion by 2027.
The key factors driving the APAC schizophrenia drugs market are government support systems, focus by public and private healthcare companies, availability of associated drugs, and growing awareness about mental health diseases. The increasing burden of this disease will negatively affect a person's overall productivity; hence, schools and companies are making efforts to raise awareness and provide adequate treatment to the patients. According to the World Health Organization report, schizophrenia affects over 20 million people worldwide. Reports also suggest that older people are more susceptible to late-onset schizophrenia. According to the World Aging report, there were approximately 705 million people aged 65 and over in the world in 2019. The number of older people is anticipated to double to 1.55 billion by 2050. The world population aged 65 and over increased from 6.85% in 1990 to 9.23% in 2019. These factors mentioned above are anticipated to boost the market by providing growth opportunities for key market players to grow in the future.
Countries of the APAC region have a high prevalence of mental health disorders due to social issues and lifestyle choices. According to the WHO, more than 309.6 million people suffer from depression, and more than 800,550 people commit suicide each year. In 2020, South Korea's suicide rate reached 25.79 deaths per 100,000 population. According to the last reports, the annual prevalence of depression in South Korea was 5.94%, which is a high number.
However, the increase in drug addiction cases associated with antipsychotic drugs, lack of reimbursement coverage for pricey mediation, inadequate treatment, social stigma, and negligence related to mental health disorders are predicted to be restraining the growth of the APAC schizophrenia drugs market during the forecast period.
This research report on the APAC schizophrenia drugs market has been segmented and sub-segmented into the following categories.
By Therapeutic Class:
- Second generation anti-psychotics
- Risperdal
- Invega
- Zyprexa
- Geodon
- Seroquel
- Latuda
- Aristada
- Fanapt
- Saphris
- Vraylar
- Third generation anti-psychotics
- Others
By Treatment:
- Oral anti-psychotics
- Injectable anti-psychotics
By Country:
- India
- China
- Japan
- South Korea
- Australia
- New Zealand
- Thailand
- Malaysia
- Vietnam
- Philippines
- Indonesia
- Singapore
- Rest of APAC
The Chinese regional market is projected to dominate the studied market during the forecast period. This market growth can be attributed to hectic lifestyles, social healthcare reforms prioritizing mental health diseases, advanced health care, and a large population driving the market in this region during the forecast period. Based on the reports collected from the China Mental Health Survey, it was found that the lifetime prevalence of any psychiatric disorder was over 16%, and the 12-month prevalence was recorded at 9.55% in the population. Furthermore, the estimated prevalence of schizophrenia in the early 1990s was recorded at 3.92 per 1,000 population, resulting in an estimated prevalence of 4.45 million cases. This prevalence is less than half of that estimated for developed countries with 8.98 / 1000. Moreover, technological advancements in the development of new drugs increased clinical trials for various drugs combined for better results, and fewer side effects aim to boost this market.
The Regional markets in Japan, India, Australia, and Taiwan are expected to have good CAGR growth in the years to come. The main factors driving the market are increasing healthcare expenditure, well-established healthcare infrastructure, growing emphasis on R&D, government initiatives, awareness programs, and early diagnosis kits. The annual prevalence of schizophrenia estimated in India was reported to be at 3.37/1000.
KEY MARKET PLAYERS:
Some of the major companies dominating the market by their products and services include Johnson & Johnson, Sumitomo Dainippon, Eli Lilly, Bristol-Myers Squibb/ Otsuka Pharma, AstraZeneca, Alkermes, Vanda Pharma, Allergan, and Pfizer.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Therapeutic class
5.1.1 Introduction
5.1.2 Second generation anti-psychotics
5.1.2.1 Risperdal
5.1.2.2 Invega
5.1.2.3 Zyprexa
5.1.2.4 Geodon
5.1.2.5 Seroquel
5.1.2.6 Latuda
5.1.2.7 Aristada
5.1.2.8 Fanapt
5.1.2.9 Saphris
5.1.2.10 Vraylar
5.1.3 Third generation anti-psychotics
5.1.4 Others
5.1.5 Y-o-Y Growth Analysis, By Therapeutic class
5.1.6 Market Attractiveness Analysis, By Therapeutic class
5.1.7 Market Share Analysis, By Therapeutic class
5.2 Treatment
5.2.1 Introduction
5.2.2 Oral anti-psychotics
5.2.3 Injectable anti-psychotics
5.2.4 Y-o-Y Growth Analysis, By Treatment
5.2.5 Market Attractiveness Analysis, By Treatment
5.2.6 Market Share Analysis, By Treatment
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Therapeutic class
6.1.3.3 By Treatment
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Therapeutic class
6.1.4.3 By Treatment
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 Therapeutic class
6.1.5.3 By Treatment
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Johnson & Johnson
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Bristol-Myers Squibb
8.3 AstraZeneca
8.4 Sumitomo Dainippon
8.5 Eli Lilly
8.6 Alkermes
8.7 Vanda Pharma
8.8 Allergan
8.9 Pfizer
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
- Asia Pacific Schizophrenia Drugs Market, By Therapeutic class, From 2022 - 2027 (USD Billion)
- Asia Pacific Second generation anti-psychotics Market, By Region, From 2022 - 2027 (USD Billion)
- Asia Pacific Third generation anti-psychotics Market, By Region, From 2022 - 2027 (USD Billion)
- Asia Pacific Others Market, By Region, From 2022 - 2027 (USD Billion)
- Asia Pacific Schizophrenia Drugs Market, By Treatment, From 2022 - 2027 (USD Billion)
- Asia Pacific Oral anti-psychotics Market, By Region, From 2022 - 2027 (USD Billion)
- Asia Pacific Injectable anti-psychotics Market, By Region, From 2022 - 2027 (USD Billion)
- Japan Schizophrenia Drugs Market, By Therapeutic class, From 2022 - 2027 (USD Billion)
- Japan Schizophrenia Drugs Market, By Treatment, From 2022 - 2027 (USD Billion)
- China Schizophrenia Drugs Market, By Therapeutic class, From 2022 - 2027 (USD Billion)
- China Schizophrenia Drugs Market, By Treatment, From 2022 - 2027 (USD Billion)
- India Schizophrenia Drugs Market, By Therapeutic class, From 2022 - 2027 (USD Billion)
- India Schizophrenia Drugs Market, By Treatment, From 2022 - 2027 (USD Billion)
- Australia Schizophrenia Drugs Market, By Therapeutic class, From 2022 - 2027 (USD Billion)
- Australia Schizophrenia Drugs Market, By Treatment, From 2022 - 2027 (USD Billion)
- South Korea Schizophrenia Drugs Market, By Therapeutic class, From 2022 - 2027 (USD Billion)
- South Korea Schizophrenia Drugs Market, By Treatment, From 2022 - 2027 (USD Billion)
Related Reports
ASK FOR CUSTOMIZATION
Talk to our analyst and get customised report done according to your research needs
INQUIRE FOR DISCOUNT
Check if you can avail any discount. Submit your details and our team will get back to you.
DOWNLOAD FREE SAMPLE
Request to avail a free sample report that reflects this market and its growth.
